F. Abell

Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy.

M. Links, C. Fox, P. Clingan, 2006, Australasian radiology.

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

R. Laing, S. Chan, L. Fehrenbacher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non‐small‐cell lung cancer: Is thrombocytopenia predictable?

C. Karapetis, P. de Souza, W. I. Burns, 2009 .

Efficacy of erlotinib in patients with advanced Non‐small‐cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study

N. Pavlakis, M. Millward, D. Rischin, 2012, Asia-Pacific journal of clinical oncology.

1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)

R. Laing, L. Fehrenbacher, R. Roylance, 2015 .